Stephen M Fowler

List of Publications by Year
in descending order

44	1,069	394421	434195
papers	citations	19 h-index	31 g-index

46	46	46	1204
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	In Vitro Evaluation of Reversible and Irreversible Cytochrome P450 Inhibition: Current Status on Methodologies and their Utility for Predicting Drugâ€“Drug Interactions. AAPS Journal, 2008, 10, 410-424.	4.4	153
2	Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects Modeling. AAPS Journal, 2017, 19, 534-550.	4.4	78
3	Minimizing DILI risk in drug discovery â€" A screening tool for drug candidates. Toxicology in Vitro, 2015, 30, 429-437.	2.4	71
4	Microphysiological systems for ADME-related applications: current status and recommendations for system development and characterization. Lab on A Chip, 2020, 20, 446-467.	6.0	66
5	A UGT2B10 Splicing Polymorphism Common in African Populations May Greatly Increase Drug Exposure. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 358-367.	2.5	46
6	Amino Acid 305 Determines Catalytic Center Accessibility in CYP3A4â€. Biochemistry, 2000, 39, 4406-4414.	2.5	38
7	Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities. Current Pharmacology Reports, 2017, 3, 36-49.	3.0	36
8	CYP3A4 Active Site Volume Modification by Mutagenesis of Leucine 211. Drug Metabolism and Disposition, 2002, 30, 452-456.	3.3	29
9	Mass Spectrometry-Based Quantification of CYP Enzymes to Establish In Vitro/In Vivo Scaling Factors for Intestinal and Hepatic Metabolism in Beagle Dog. Pharmaceutical Research, 2012, 29, 1832-1842.	3.5	29
10	The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics, 2019, 58, 189-211.	3.5	29
11	Nonclinical Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in the Central Nervous System. Antimicrobial Agents and Chemotherapy, 2009, 53, 4753-4761.	3.2	28
12	Characterization of the Ontogeny of Hepatic UDPâ€Glucuronosyltransferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes. Journal of Clinical Pharmacology, 2019, 59, S42-S55.	2.0	26
13	Cytochrome P-450cam monooxygenase can be redesigned to catalyse the regioselective aromatic hydroxylation of diphenylmethane. Journal of the Chemical Society Chemical Communications, 1994, , 2761.	2.0	25
14	Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatographyâ€“Tandem Mass Spectrometry. Drug Metabolism and Disposition, 2019, 47, 124-134.	3.3	25
15	A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clinical Therapeutics, 2009, 31, 586-599.	2.5	24
16	In vitroprofiling of the metabolism and drugâ€“drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobiotica, 2015, 45, 230-238.	1.1	24
17	Humanizing the zebrafish liver shifts drug metabolic profiles and improves pharmacokinetics of CYP3A4 substrates. Archives of Toxicology, 2017, 91, 1187-1197.	4.2	24
18	In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Current Medical Research and Opinion, 2009, 25, 891-902.	1.9	23

#	Article	IF	Citations
19	Exploration and application of a liver-on-a-chip device in combination with modelling and simulation for quantitative drug metabolism studies. Lab on A Chip, 2022, 22, 1187-1205.	6.0	22
20	Modelâ€Based Assessments of CYPâ€Mediated Drugâ€“Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development. Clinical Pharmacology and Therapeutics, 2018, 104, 505-514.	4.7	20
21	Application of the Extended Clearance Classification System (ECCS) in Drug Discovery and Development: Selection of Appropriate In Vitro Tools and Clearance Prediction. Drug Metabolism and Disposition, 2020, 48, 849-860.	3.3	20
22	In Vitro to in Vivo Extrapolation and Physiologically Based Modeling of Cytochrome P450 Mediated Metabolism in Beagle Dog Gut Wall and Liver. Molecular Pharmaceutics, 2013, 10, 1388-1399.	4.6	19
23	In Vitro to In Vivo Extrapolation of Metabolic Clearance for UGT Substrates Using Short-Term Suspension and Long-Term Co-cultured Human Hepatocytes. AAPS Journal, 2020, 22, 131.	4.4	18
24	Application of a gutâ€“liver-on-a-chip device and mechanistic modelling to the quantitative in vitro pharmacokinetic study of mycophenolate mofetil. Lab on A Chip, 2022, 22, 2853-2868.	6.0	18
25	In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes. Xenobiotica, 2018, 48, 546-554.	1.1	16
26	Application of New Cellular and Microphysiological Systems to Drug Metabolism Optimization and Their Positioning Respective to In Silico Tools. SLAS Discovery, 2019, 24, 523-536.	2.7	16
27	Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine. AAPS Journal, 2020, 22, 128.	4.4	16
28	Monitoring Cyp2b10 mRNA expression at cessation of 2-year carcinogenesis bioassay in mouse liver provides evidence for a carcinogenic mechanism devoid of human relevance: The dalcetrapib experience. Toxicology and Applied Pharmacology, 2012, 259, 355-365.	2.8	15
29	Simultaneous Assessment of Clearance, Metabolism, Induction, and Drug-Drug Interaction Potential Using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 237-248.	2.5	13
30	Impact of Intracellular Concentrations on Metabolic Drug-Drug Interaction Studies. AAPS Journal, 2019, 21, 77.	4.4	13
31	In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK). Investigational New Drugs, 2022, 40, 68-80.	2.6	11
32	Effects of Cytochrome P450 3A4 Inhibitorsâ€”Ketoconazole and Erythromycinâ€”on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions. Clinical Pharmacokinetics, 2016, 55, 237-247.	3.5	10
33	Comments on â€œAnti-Influenza Prodrug Oseltamivir Is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation Is Inhibited by Antiplatelet Agent Clopidogrelâ€. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 422-423.	2.5	9
34	Low Potential of Basimglurant to Be Involved in Drug-Drug Interactions: Influence of Nonâ€“Michaelis-Menten P450 Kinetics on Fraction Metabolized. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 164-173.	2.5	7
35	Characterization of Hepatic UDP-Glucuronosyltransferase Enzyme Abundance-Activity Correlations and Population Variability Using a Proteomics Approach and Comparison with Cytochrome P450 Enzymes. Drug Metabolism and Disposition, 2021, 49, 760-769.	3.3	7
36	Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 779-791.	1.6	7

#	Article	IF	Citations
37	Addressing Todayâ€™s Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of theSMN2mRNA Splicing Modifier Risdiplam. Drug Metabolism and Disposition, 2022, 50, 65-75.	3.3	7
38	Estimation of Fraction Metabolized by Cytochrome P450 Enzymes Using Long-Term Cocultured Human Hepatocytes. Drug Metabolism and Disposition, 2022, 50, 566-575.	3.3	7
39	Shedding light on minipig drug metabolism â€“ elevated amide hydrolysisin vitro. Xenobiotica, 2016, 46, 483-494.	1.1	6
40	Use of Phenotypically Poor Metabolizer Individual Donor Human Liver Microsomes To Identify Selective Substrates of UGT2B10. Drug Metabolism and Disposition, 2020, 48, 176-186.	3.3	6
41	The In Vitro Biotransformation of the Fusion Protein Tetranectin-Apolipoprotein A1. Scientific Reports, 2019, 9, 4074.	3.3	4
42	Coexpression of Human Hepatic Uridine Diphosphate Glucuronosyltransferase Proteins: Implications for Ontogenetic Mechanisms and Isoform Coregulation. Journal of Clinical Pharmacology, 2020, 60, 722-733.	2.0	4
43	Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drugâ€“Drug Interactions. Drug Metabolism and Disposition, 2022, 50, 214-223.	3.3	1
44	A novel zebrafish model to predict organ toxicities in mammals. Toxicology Letters, 2013, 221, S233-S234.	0.8	0